December 19, 2014
A new injectable medication for the treatment of alcohol dependence, as well as a novel pharmacotherapy for nicotine addiction, were the focus of the American Psychiatric Association’s update to its Practice Guideline for the Treatment of Patients with Substance Abuse Disorders, 2nd Edition
The update in 2007 supplements the information and recommendations published in the 2006 version of the guideline. It provided additional evidence in favor of a long-acting, injectable form of the drug naltrexone, which was FDA approved in oral form for the treatment of alcohol dependence in 1994. The efficacy of the oral form was limited by patient noncompliance to the regimen.